You are here

Article Text

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results
  1. Hossein Borghaei1,
  2. Michael Boyer2,
  3. Melissa Johnson3,
  4. Ramaswamy Govindan4,
  5. Luis Paz-Ares Rodrigues5,
  6. Fiona Blackhall6,
  7. Rene Boosman7,
  8. Stéphane Champiat8,
  9. Horst-Dieter Hummel9,
  10. W Victoria Lai10,
  11. Hibiki Udagawa11,
  12. Anne Chiang12,
  13. Afshin Dowlati13,
  14. Christine Hann14,
  15. Ravi Salgia15,
  16. Everett Vokes16,
  17. Mukul Minocha17,
  18. Nooshin Hashemi-Sadraei17,
  19. Aditya Shetty17,
  20. Marie-Anne Damiette Smit17,
  21. Hui Yang17 and
  22. Taofeek Owonikoko18
  1. 1Fox Chase Cancer Center, Philadelphia, PA, USA
  2. 2Chris O’Brien Lifehouse, Camperdown, Australia
  3. 3Sarah Cannon Research Institute, Tenness, Nashville, TN, USA
  4. 4Washington University Medical School, Saint Louis, MO, USA
  5. 5Universidad Complutense and Ciberonc, Madrid, Spain
  6. 6University of Manchester, Manchester, UK
  7. 7The Netherlands Cancer Institute, Amsterdam, Netherlands
  8. 8Paris-Saclay University, Villejuif, France
  9. 9University Hospital Wuerzburg, Wuerzburg, Germany
  10. 10Memorial Sloan Kettering Cancer Center, New York, NY, USA
  11. 11National Cancer Center Hospital East, Kashiwa, China
  12. 12Yale School of Medicine, New Haven, CT, USA
  13. 13University Hospitals Seidman Cancer Ctr, Cleveland, OH, USA
  14. 14Sidney Kimmel Comprehensive Cancer Cente, Baltimore, MD, USA
  15. 15City of Hope, Duarte, CA, USA
  16. 16University of Chicago Medicine and Biolo, Chicago, IL, USA
  17. 17Amgen Inc., Thousand Oaks, CA, USA
  18. 18Emory University School of Medicine, Atlanta, GA, USA

Abstract

Background Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand that is highly expressed in small cell lung cancer (SCLC) and minimally expressed in normal tissues.1 AMG 757, a half-life extended BiTE® immune therapy, binds to DLL3 on tumor cells and CD3 on T cells, resulting in T cell-dependent killing of tumor cells. We report initial safety and efficacy from the ongoing phase 1 study of AMG 757 in patients with SCLC.

Methods AMG 757 was administered intravenously every two weeks (with/without step dose) at doses of 0.003–3.0 mg. Eligible patients had SCLC that progressed or recurred following ≥1 platinum-based regimen. Antitumor activity was assessed using modified RECIST 1.1. The study was approved by the Ethics Board at participating institutions.

Results As of 1 June 2020, safety and efficacy data are available for 31 patients enrolled at the first seven dose levels (DL) with median age, 63 (44–74) years; ECOG PS: 0–1, n=30 (96.8%); median prior lines, 2.0 (1–6); and previous PD-1/PD-L1 treatment: n=12 (38.7%). Median treatment duration was 6.1 (0.1–59.4) weeks. Treatment-emergent adverse events (AEs) were reported for 30 (96.8%) patients. AMG 757-related AEs occurred in 25 (80.6%) patients, including 5 (16.1%) that were grade ≥3 and one (3.2%) grade 5 (pneumonitis in DL5 [0.3 mg]). Three AEs (dyspnea, pneumonitis, fatigue) led to treatment discontinuation. The most common AE was cytokine release syndrome (CRS), which was reported in 11 (35.5%) patients. CRS AEs were grade 1–2, consisted mainly of fever with/without hypotension, and occurred mostly within 24 hours of the first or second dose of AMG 757. CRS events were reversible, did not lead to treatment interruption or discontinuation, and were managed with supportive care, corticosteroids, and/or anti-IL 6 therapy. The MTD for AMG 757 has not yet been reached. AMG 757 exhibited dose proportional increase in exposures. Response to AMG 757 is shown (figure 1). Confirmed partial response was reported in 5 (16.1%) patients (1/12 [8.3%] in DL5, 1/8 [12.5%] in DL6, 3/7 [42.9%] in DL7), and stable disease in 8 (25.8%) of all treated patients. Most responses occurred after 8 weeks on treatment. All responders remain on treatment with duration of response ranging from 2.0+ to 7.4 months+.

Abstract 359 Figure 1
Abstract 359 Figure 1

Tumor shrinkage over time in response to AMG 757

Conclusions AMG 757 administered at a dose of up to 3 mg every two weeks has an acceptable safety profile and shows anti-tumor activity in patients with relapsed/refractory SCLC. Further dose escalation is ongoing.

Trial Registration NCT03319940

Ethics Approval The study was approved by the Ethics Board at participating institutions.

Consent N/A

Reference

  1. Leonetti A, Facchinetti F, Minari R, Cortellini A, Rolfo CD, Giovannetti E, Tiseo M. Cell Oncol (Dordr). 2019;42:261–273.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0359

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.